India's Ranbaxy Sees 53 Percent Sales Drop In Wake Of U.S. FDA Action
This article was originally published in PharmAsia News
Executive Summary
The problems India's Ranbaxy Laboratories encountered with the U.S. FDA last year were reflected in the company's reported U.S. sales drop of 53 percent during the third quarter of this year